Precision BioSciences, Inc.

NasdaqCM:DTIL Stock Report

Market Cap: US$36.2m

Precision BioSciences Management

Management criteria checks 3/4

Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 3.17 years. total yearly compensation is $2.04M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $134.70K. The average tenure of the management team and the board of directors is 2.9 years and 4.2 years respectively.

Key information

Michael Amoroso

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage30.9%
CEO tenure3.2yrs
CEO ownership0.4%
Management average tenure2.9yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06
Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23
It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14
Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08
Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Aug 16

Precision BioSciences Q2 2022 Earnings Preview

Aug 05

Precision Bio: Another CAR-T Laggard With No Solid Prospects

May 09

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19
Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21
Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31
Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

CEO Compensation Analysis

How has Michael Amoroso's remuneration changed compared to Precision BioSciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$11m

Jun 30 2024n/an/a

US$16m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$2mUS$630k

-US$43m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$4mUS$604k

-US$73m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$6mUS$127k

-US$31m

Compensation vs Market: Michael's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


CEO

Michael Amoroso (46 yo)

3.2yrs

Tenure

US$2,039,281

Compensation

Mr. Michael Amoroso is Chairman of Abeona Therapeutics LLC. Mr. Amoroso serves as Director, President and Chief Executive Officer of Precision BioSciences, Inc. since October 15, 2021. He serves as Directo...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Amoroso
President3.2yrsUS$2.04m0.37%
$ 134.7k
John Kelly
CFO & Principal Accounting Officer3.9yrsUS$1.08m0.50%
$ 179.7k
Jefferson Smith
Co-Founder & Chief Research Officerno datano data1.0%
$ 361.0k
Naresh Tanna
Chief of Staff to CEO & Head of Investor Relationsless than a yearno datano data
Dario Scimeca
General Counsel & Secretary5.5yrsUS$1.51m0.10%
$ 37.6k
Bruce Stevens
Vice President of Quality & Compliance4.9yrsno datano data
Maurissa Messier
Senior Director of Corporate Communicationsno datano datano data
Juli Blanche
Chief People Officer2.6yrsno datano data
Garrett Gincley
Head of Manufacturingno datano datano data
Cindy Atwell
Chief Business Officerno datano datano data
Neil Leatherbury
Senior VP and Head of Chemistry1.8yrsno datano data
Murray Abramson
Senior VP & Head of Clinical Developmentless than a yearno datano data

2.9yrs

Average Tenure

50yo

Average Age

Experienced Management: DTIL's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Amoroso
President3.2yrsUS$2.04m0.37%
$ 134.7k
Kenneth Anderson
Member of Scientific Advisory Board5.9yrsno datano data
Hagop M. Kantarjian
Member of Scientific Advisory Board5.9yrsno datano data
Raymond Schinazi
Member of Scientific Advisory Board5.9yrsUS$256.47kno data
Kevin Buehler
Independent Lead Director5.1yrsUS$188.49k0.057%
$ 20.7k
Alan List
Clinical Consultant & Member of Scientific Advisory Boardless than a yearUS$909.97k0.059%
$ 21.2k
Geno Germano
Independent Director4.8yrsUS$169.74k0.055%
$ 19.8k
Samuel Wadsworth
Independent Director3.1yrsUS$149.99k0.055%
$ 19.8k
Shari Pire
Independent Director3.1yrsUS$158.90k0.055%
$ 19.8k
Melinda Brown
Independent Director2.6yrsUS$158.99k0.055%
$ 19.8k
Cameron Turtle
Member of Scientific Advisory Board5.9yrsno datano data
Stanley Frankel
Independent Director3.7yrsUS$156.24k0.055%
$ 20.1k

4.2yrs

Average Tenure

67yo

Average Age

Experienced Board: DTIL's board of directors are considered experienced (4.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Precision BioSciences, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.